Chimeric Antigen Receptor T-cell Therapy for Melanoma.

Chimeric Antigen Receptor T-cell Therapy for Melanoma. Expert Rev Clin Immunol. 2021 Jan 22;: Authors: Razavi A, Keshavarz-Fathi M, Pawelek J, Rezaei N Abstract INTRODUCTION: In recent years, chimeric antigen receptor (CAR) T cell therapy has emerged for cancer treatment. After initial therapeutic success for hematologic malignancies, this approach has been extended for treatment of solid tumors including melanoma. AREAS COVERED: T cells need to be reprogramed to recognize specific antigens expressed only on tumor cells, a difficult problem since cancer cells are simply transformed normal cells. Tumor antigens, namely CSPG4, CD70, and GD2 have been targeted by CAR-T cells for melanoma. Moreover, different co-stimulatory signaling domains need to be selected to direct T cell fate. In this review, various approaches for treatment of melanoma and their effectiveness is comprehensively reviewed and the current status, challenges, and future perspective of CAR-T cell therapy for melanoma are discussed. Literature search was accomplished in three databases (PubMed, Google scholar, and Clinicaltrials.gov). Published papers and clinical trials were screened and relevant documents were included by checking pre-defined eligibility criteria. EXPERT OPINION: Despite obstacles and risk of adverse events, CAR T cell therapy could be used for patients with treatment resistant cancer. Clinical trials are underway to determine the eff...
Source: Expert Review of Clinical Immunology - Category: Allergy & Immunology Tags: Expert Rev Clin Immunol Source Type: research